NextCure's macrophage-based alternative to T cell checkpoint inhibitors

A study led by NextCure co-founder and PD-1 pioneer Lieping Chen has found that blocking SIGLEC15 could boost antitumor T cell responses in immunosuppressive tumor microenvironments.

NextCure Inc. (Beltsville, Md.) is testing anti-SIGLEC15 mAb NC318 in a Phase I/II trial to treat solid tumors...